Edgar Filing: NAVIDEA BIOPHARMACEUTICALS, INC. - Form 4

NAVIDEA B Form 4 July 21, 2015	BIOPHARMACE	UTICAL	.S, INC.								
FORM						OMB APPROVAL					
		ITIES A hington,			NGE C	COMMISSION	OMB Number:	3235-0287			
Check thi if no long subject to Section 10 Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	er STATEM 6. Filed pure inue. Section 17(a	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							Expires: January 31 200 Estimated average burden hours per response 0.		
(Print or Type R	Responses)										
DRAKE PETER F Symbol NAV BIOF			Symbol NAVID	VIDEA PHARMACEUTICALS, INC.				 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner 			
(Last) 5600 BLAZI 200	(First) (N ER PARKWAY,	fiddle) SUITE	3. Date of Earliest Transaction (Month/Day/Year)				Officer (give below)	or (specify			
DUBLIN, O	(Street) H US 43017		4. If Amendment, Date Original Filed(Month/Day/Year)					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	ecuri	ties Aca	uired, Disposed of	, or Beneficial	lv Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Executio any		3.		ies Ac sposed	quired of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	•	
Common Stock	07/16/2015			D <u>(1)</u>	22,000	D	\$ 0.01	77,829 (2)	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	(Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: NAVIDEA BIOPHARMACEUTICALS, INC. - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
DRAKE PETER F 5600 BLAZER PARKWAY, SUITE 20 DUBLIN, OH US 43017	0 X							
Signatures								
William J. Kelly, attorney-in-fact	07/21/2015							
<u>**</u> Signature of Reporting Person	Date							

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Time vested restricted stock award on 3/26/2015, reported on Form 4 filed 3/30/2015, failed to vest due to early termination of director status, and has been cancelled.
- (2) Reflects a 10 share correction in holdings reported on Form 4 filed 3/30/2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.